Politis DS, Katsanos KH, Papamichael K, Saridi M, Albani E, Christodoulou DK. Has the time been reached for pseudopolyps to be re-enrolled in endoscopic inflammatory bowel disease scores? World J Gastrointest Endosc 2019; 11(6): 424-426 [PMID: 31236195 DOI: 10.4253/wjge.v11.i6.424]
Corresponding Author of This Article
Dimitrios S Politis, FEBGH, MD, PhD, Doctor, Department of Gastroenterology, University Hospital of Ioannina, Faculty of Medicine, School of Health Sciences, University of Ioannina, Leoforos Stavrou Niarchou, Ioannina 45110, Greece. politisdimitrios1@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letters To The Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Endosc. Jun 16, 2019; 11(6): 424-426 Published online Jun 16, 2019. doi: 10.4253/wjge.v11.i6.424
Has the time been reached for pseudopolyps to be re-enrolled in endoscopic inflammatory bowel disease scores?
Dimitrios S Politis, Konstantinos H Katsanos, Konstantinos Papamichael, Maria Saridi, Eleni Albani, Dimitrios K Christodoulou
Dimitrios S Politis, Konstantinos H Katsanos, Dimitrios K Christodoulou, Department of Gastroenterology, University Hospital of Ioannina, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina 45110, Greece
Konstantinos Papamichael, Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth-Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, United States
Maria Saridi, General Hospital of Corinth, Department of Social and Educational Policy, University of Peloponnese, Corinth 20100, Greece
Eleni Albani, Department of Nursing, TEI of Western Greece, Patra 26334, Greece
Author contributions: All authors contributed to the conception, literature review, drafting and revising of the manuscript, and provided approval of the final form.
Conflict-of-interest statement: All authors declare no conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Dimitrios S Politis, FEBGH, MD, PhD, Doctor, Department of Gastroenterology, University Hospital of Ioannina, Faculty of Medicine, School of Health Sciences, University of Ioannina, Leoforos Stavrou Niarchou, Ioannina 45110, Greece. politisdimitrios1@gmail.com
Telephone: +30-26510-99867 Fax: +30-26510-07016
Received: May 5, 2019 Peer-review started: May 8, 2019 First decision: May 31, 2019 Revised: June 5, 2019 Accepted: June 10, 2019 Article in press: June 10, 2019 Published online: June 16, 2019 Processing time: 42 Days and 12.2 Hours
Abstract
Patients with inflammatory bowel diseases (IBD) represent heterogeneous groups with different characteristics and different clinical course. A great deal of effort is made to discover proxies for more severe disease needing more intense treatment and early intervention to gain the maximum therapeutic benefit. Endoscopy remains an invaluable method in assessment of patients with IBD. Pseudopolyps are often encountered during endoscopy and, although they are a well described entity, their presence is of unclear importance. In one of our recent studies and in conjunction with one study with a large cohort of patients with IBD and pseudopolyps, patients with pseudopolyps were found to face a higher inflammatory burden in terms of receiving more intense biological treatment. This letter comes as a comment and proposition regarding the concept of re-evaluation of pseudopolyps as a promising marker in IBD scores.
Core tip: Interest in pseudopolyps and their relationship for monitoring inflammatory bowel disease activity has been refreshed by two recent studies that showed the presence of pseudopolyps to be linked with escalation of treatment, including the increased need for use of biological agents. The next logical step in their management is including their evaluation and possible integration, after proper validation, in inflammatory bowel disease scores, as separate markers for prediction of a more severe clinical course.
